Cargando…
Baseline and interim [18F]FDG-PET/MRI to assess treatment response and survival in patients with M0 esophageal squamous cell carcinoma treated by curative-intent therapy
BACKGROUND: To investigate the value of [18F]FDG-PET/MRI in predicting treatment response and survival in patients with primary M0 esophageal squamous cell carcinoma. METHODS: Patients with esophageal squamous cell carcinoma received [18F]FDG-PET/MRI at baseline and during neoadjuvant or definitive...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629192/ https://www.ncbi.nlm.nih.gov/pubmed/37932848 http://dx.doi.org/10.1186/s40644-023-00630-2 |
_version_ | 1785131914677452800 |
---|---|
author | Chao, Yin-Kai Chang, Chun-Bi Chang, Yu-Chuan Chan, Sheng-Chieh Chiu, Chien-Hung Ng, Shu-Hang Hsieh, Jason Chia-Hsun Wang, Jen-Hung |
author_facet | Chao, Yin-Kai Chang, Chun-Bi Chang, Yu-Chuan Chan, Sheng-Chieh Chiu, Chien-Hung Ng, Shu-Hang Hsieh, Jason Chia-Hsun Wang, Jen-Hung |
author_sort | Chao, Yin-Kai |
collection | PubMed |
description | BACKGROUND: To investigate the value of [18F]FDG-PET/MRI in predicting treatment response and survival in patients with primary M0 esophageal squamous cell carcinoma. METHODS: Patients with esophageal squamous cell carcinoma received [18F]FDG-PET/MRI at baseline and during neoadjuvant or definitive chemoradiotherapy. The treatment response was classified according to the Response Evaluation Criteria for Solid Tumors 1.1. We used Kaplan-Meier and Cox regression analyses to assess the association between PET/MRI parameters and overall survival (OS) or progression-free survival (PFS). RESULTS: We included 40 M0 patients in the final analysis. The volume transfer constant (K(trans)) from baseline PET/MRI (area under the curve (AUC) = 0.688, P = 0.034) and total lesion glycolysis (TLG) from baseline PET/MRI (AUC = 0.723, P = 0.006) or interim PET/MRI (AUC = 0.853, P < 0.001) showed acceptable AUC for predicting treatment response. The TLG from interim PET/MRI (interim TLG, P < 0.001) and extracellular volume fraction (Ve) on interim PET/MRI (interim Ve, P = 0.001) were identified as independent prognostic factors for OS. Baseline Ve (P = 0.044) and interim TLG (P = 0.004) were significant predictors of PFS. The c-indices of the prognostic models combining interim TLG with Ve for predicting OS, and baseline Ve and interim TLG for predicting PFS were 0.784 and 0.699, respectively. These values were significantly higher than the corresponding c-indices of the TNM staging system (P = 0.002 and P = 0.047, respectively). CONCLUSIONS: Combining the baseline and interim [18F]FDG-PET/MRI qualitative imaging parameters aids in predicting the prognosis of patients with M0 esophageal squamous cell carcinoma. TRIAL REGISTRATION: The study was registered at Clinicaltrials.gov (identifier: NCT 05855291 and NCT 05855278). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40644-023-00630-2. |
format | Online Article Text |
id | pubmed-10629192 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-106291922023-11-08 Baseline and interim [18F]FDG-PET/MRI to assess treatment response and survival in patients with M0 esophageal squamous cell carcinoma treated by curative-intent therapy Chao, Yin-Kai Chang, Chun-Bi Chang, Yu-Chuan Chan, Sheng-Chieh Chiu, Chien-Hung Ng, Shu-Hang Hsieh, Jason Chia-Hsun Wang, Jen-Hung Cancer Imaging Research Article BACKGROUND: To investigate the value of [18F]FDG-PET/MRI in predicting treatment response and survival in patients with primary M0 esophageal squamous cell carcinoma. METHODS: Patients with esophageal squamous cell carcinoma received [18F]FDG-PET/MRI at baseline and during neoadjuvant or definitive chemoradiotherapy. The treatment response was classified according to the Response Evaluation Criteria for Solid Tumors 1.1. We used Kaplan-Meier and Cox regression analyses to assess the association between PET/MRI parameters and overall survival (OS) or progression-free survival (PFS). RESULTS: We included 40 M0 patients in the final analysis. The volume transfer constant (K(trans)) from baseline PET/MRI (area under the curve (AUC) = 0.688, P = 0.034) and total lesion glycolysis (TLG) from baseline PET/MRI (AUC = 0.723, P = 0.006) or interim PET/MRI (AUC = 0.853, P < 0.001) showed acceptable AUC for predicting treatment response. The TLG from interim PET/MRI (interim TLG, P < 0.001) and extracellular volume fraction (Ve) on interim PET/MRI (interim Ve, P = 0.001) were identified as independent prognostic factors for OS. Baseline Ve (P = 0.044) and interim TLG (P = 0.004) were significant predictors of PFS. The c-indices of the prognostic models combining interim TLG with Ve for predicting OS, and baseline Ve and interim TLG for predicting PFS were 0.784 and 0.699, respectively. These values were significantly higher than the corresponding c-indices of the TNM staging system (P = 0.002 and P = 0.047, respectively). CONCLUSIONS: Combining the baseline and interim [18F]FDG-PET/MRI qualitative imaging parameters aids in predicting the prognosis of patients with M0 esophageal squamous cell carcinoma. TRIAL REGISTRATION: The study was registered at Clinicaltrials.gov (identifier: NCT 05855291 and NCT 05855278). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40644-023-00630-2. BioMed Central 2023-11-06 /pmc/articles/PMC10629192/ /pubmed/37932848 http://dx.doi.org/10.1186/s40644-023-00630-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Chao, Yin-Kai Chang, Chun-Bi Chang, Yu-Chuan Chan, Sheng-Chieh Chiu, Chien-Hung Ng, Shu-Hang Hsieh, Jason Chia-Hsun Wang, Jen-Hung Baseline and interim [18F]FDG-PET/MRI to assess treatment response and survival in patients with M0 esophageal squamous cell carcinoma treated by curative-intent therapy |
title | Baseline and interim [18F]FDG-PET/MRI to assess treatment response and survival in patients with M0 esophageal squamous cell carcinoma treated by curative-intent therapy |
title_full | Baseline and interim [18F]FDG-PET/MRI to assess treatment response and survival in patients with M0 esophageal squamous cell carcinoma treated by curative-intent therapy |
title_fullStr | Baseline and interim [18F]FDG-PET/MRI to assess treatment response and survival in patients with M0 esophageal squamous cell carcinoma treated by curative-intent therapy |
title_full_unstemmed | Baseline and interim [18F]FDG-PET/MRI to assess treatment response and survival in patients with M0 esophageal squamous cell carcinoma treated by curative-intent therapy |
title_short | Baseline and interim [18F]FDG-PET/MRI to assess treatment response and survival in patients with M0 esophageal squamous cell carcinoma treated by curative-intent therapy |
title_sort | baseline and interim [18f]fdg-pet/mri to assess treatment response and survival in patients with m0 esophageal squamous cell carcinoma treated by curative-intent therapy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629192/ https://www.ncbi.nlm.nih.gov/pubmed/37932848 http://dx.doi.org/10.1186/s40644-023-00630-2 |
work_keys_str_mv | AT chaoyinkai baselineandinterim18ffdgpetmritoassesstreatmentresponseandsurvivalinpatientswithm0esophagealsquamouscellcarcinomatreatedbycurativeintenttherapy AT changchunbi baselineandinterim18ffdgpetmritoassesstreatmentresponseandsurvivalinpatientswithm0esophagealsquamouscellcarcinomatreatedbycurativeintenttherapy AT changyuchuan baselineandinterim18ffdgpetmritoassesstreatmentresponseandsurvivalinpatientswithm0esophagealsquamouscellcarcinomatreatedbycurativeintenttherapy AT chanshengchieh baselineandinterim18ffdgpetmritoassesstreatmentresponseandsurvivalinpatientswithm0esophagealsquamouscellcarcinomatreatedbycurativeintenttherapy AT chiuchienhung baselineandinterim18ffdgpetmritoassesstreatmentresponseandsurvivalinpatientswithm0esophagealsquamouscellcarcinomatreatedbycurativeintenttherapy AT ngshuhang baselineandinterim18ffdgpetmritoassesstreatmentresponseandsurvivalinpatientswithm0esophagealsquamouscellcarcinomatreatedbycurativeintenttherapy AT hsiehjasonchiahsun baselineandinterim18ffdgpetmritoassesstreatmentresponseandsurvivalinpatientswithm0esophagealsquamouscellcarcinomatreatedbycurativeintenttherapy AT wangjenhung baselineandinterim18ffdgpetmritoassesstreatmentresponseandsurvivalinpatientswithm0esophagealsquamouscellcarcinomatreatedbycurativeintenttherapy |